Allan B Dietz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8813714/publications.pdf

Version: 2024-02-01

185	7,787	47409	71088
papers	citations	49 h-index	80 g-index

189	189	189	11439
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections. Journal of Orthopaedic Research, 2022, 40, 712-726.	1.2	6
2	Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients. Stem Cell Research and Therapy, 2022, 13, 45.	2.4	1
3	IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Nonobstructive Coronary Arteries. Circulation Research, 2022, 130, 326-338.	2.0	17
4	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Advances, 2022, 6, 3678-3683.	2.5	42
5	Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.4	6
6	Capture and reagent exchange (CARE) wells for cell isolation, labeling, and characterization. Microfluidics and Nanofluidics, 2022, 26, .	1.0	0
7	Autophagy Is Involved in Mesenchymal Stem Cell Death in Coculture with Chondrocytes. Cartilage, 2021, 13, 969S-979S.	1.4	4
8	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. Clinical and Translational Immunology, 2021, 10, e1267.	1.7	4
9	Gene expression profiles of human adipose-derived mesenchymal stem cells dynamically seeded on clinically available processed nerve allografts and collagen nerve guides. Neural Regeneration Research, 2021, 16, 1613.	1.6	7
10	Alterations of mesenchymal stromal cells in cerebrospinal fluid: insights from transcriptomics and an ALS clinical trial. Stem Cell Research and Therapy, 2021, 12, 187.	2.4	8
11	Stem Cell Therapy for Microvascular Injury Associated with Ischemic Nephropathy. Cells, 2021, 10, 765.	1.8	6
12	Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain reaction. Cytotherapy, 2021, 23, 452-458.	0.3	1
13	Management of externally manufactured cell therapy products: the Mayo Clinic approach. Cytotherapy, 2021, 24, 19-26.	0.3	2
14	Fibroblastic differentiation of mesenchymal stem/stromal cells (MSCs) is enhanced by hypoxia in 3D cultures treated with bone morphogenetic protein 6 (BMP6) and growth and differentiation factor 5 (GDF5). Gene, 2021, 788, 145662.	1.0	3
15	Rationale and Trial Design of MesEnchymal Stem Cell Trial in Preventing Venous Stenosis of Hemodialysis Vascular Access Arteriovenous Fistula (MEST AVF Trial). Kidney360, 2021, 2, 1945-1952.	0.9	1
16	Differences in Cytotoxicity of Lidocaine, Ropivacaine, and Bupivacaine on the Viability and Metabolic Activity of Human Adipose-Derived Mesenchymal Stem Cells. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 82-91.	0.7	9
17	Hypothermia and nutrient deprivation alter viability of human adipose-derived mesenchymal stem cells. Gene, 2020, 722, 144058.	1.0	9
18	Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohnâ€™s Fistulas. Inflammatory Bowel Diseases, 2020, 26, 670-677.	0.9	40

#	Article	IF	Citations
19	Autologous Adipose Tissueâ€“Derived Mesenchymal Stem Cells Introduced by Biliary Stents or Local Immersion in Porcine Bile Duct Anastomoses. Liver Transplantation, 2020, 26, 100-112.	1.3	6
20	Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia, 2020, 34, 1383-1393.	3.3	17
21	In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascularÂdisease increases blood flow andÂtheÂglomerular filtration rate while reducing inflammatory biomarkers and blood pressure. Kidney International, 2020, 97, 793-804.	2.6	42
22	Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs. Nature Biomedical Engineering, 2020, 4, 437-445.	11.6	38
23	CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissueâ€“Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. Mayo Clinic Proceedings, 2020, 95, 406-414.	1.4	66
24	Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa105.	0.4	8
25	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nature Communications, 2020, 11, 5173.	5.8	46
26	Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid, 2020, 30, 1440-1450.	2.4	53
27	Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. Cardiovascular Research, 2020, 116, 1424-1433.	1.8	34
28	Functional expression of ZNF467 and PCBP2 supports adipogenic lineage commitment in adipose-derived mesenchymal stem cells. Gene, 2020, 737, 144437.	1.0	6
29	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro-Oncology, 2020, 22, 967-978.	0.6	62
30	Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clinical Cancer Research, 2020, 26, 1045-1053.	3.2	13
31	Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. Liver Transplantation, 2020, 26, 549-563.	1.3	9
32	Cytotoxic Effects of Nonionic Iodinated Contrast Agent on Human Adiposeâ€Đerived Mesenchymal Stem Cells. PM and R, 2019, 11, 45-55.	0.9	5
33	Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 1614-1623.	0.4	41
34	Regenerative Materials for Surgical Reconstruction: Current Spectrum of Materials and a Proposed Method for Classification. Mayo Clinic Proceedings, 2019, 94, 2099-2116.	1.4	6
35	Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology, 2019, 93, e77-e87.	1.5	62
36	Effect of Lidocaine on Viability and Gene Expression of Human Adiposeâ€“derived Mesenchymal Stem Cells: An in vitro Study. PM and R, 2019, 11, 1218-1227.	0.9	4

#	Article	IF	Citations
37	Early Results of a Phase I Trial Using an Adipose-Derived Mesenchymal Stem Cell-Coated Fistula Plug for the Treatment of Transsphincteric Cryptoglandular Fistulas. Diseases of the Colon and Rectum, 2019, 62, 615-622.	0.7	37
38	Donor-specific hypo-responsiveness occurs in simultaneous liver-kidney transplant recipients after the first year. Kidney International, 2018, 93, 1465-1474.	2.6	41
39	Osteogenic Stimulation of Human Adipose-Derived Mesenchymal Stem Cells Using a Fungal Metabolite That Suppresses the Polycomb Group Protein EZH2. Stem Cells Translational Medicine, 2018, 7, 197-209.	1.6	32
40	Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2. Gene Reports, 2018, 10, 149-156.	0.4	16
41	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research, 2018, 24, 3014-3025.	3.2	64
42	Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans. Journal of Visualized Experiments, 2018, , .	0.2	2
43	Validation of Osteogenic Properties of Cytochalasin D by High-Resolution RNA-Sequencing in Mesenchymal Stem Cells Derived from Bone Marrow and Adipose Tissues. Stem Cells and Development, 2018, 27, 1136-1145.	1.1	24
44	Profiling of human epigenetic regulators using a semi-automated real-time qPCR platform validated by next generation sequencing. Gene, 2017, 609, 28-37.	1.0	25
45	Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology, 2017, 153, 59-62.e2.	0.6	147
46	Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 2777-2785.	3.0	121
47	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2770-2780.	1.8	210
48	Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer. Advances in Radiation Oncology, 2017, 2, 540-547.	0.6	27
49	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. Cytotherapy, 2017, 19, 1426-1437.	0.3	9
50	Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. Medical Oncology, 2017, 34, 140.	1.2	1
51	Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 185-191.	1.2	7
52	A consistent, and predictable drug: The first 100 patients treated with autologous adipose derived mesenchymal stromal cells (MSCs) at the Mayo Clinic. Cytotherapy, 2017, 19, S155.	0.3	1
53	A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. , 2017, 5, 30.		64
54	Immunosuppressive CD14⁺HLA-DR^{lo/neg}monocytes are elevated in pancreatic cancer and â€œprimedâ€•by tumor-derived exosomes. OncoImmunology, 2017, 6, e1252013.	2.1	59

#	Article	IF	Citations
55	Molecular Validation of Chondrogenic Differentiation and Hypoxia Responsiveness of Platelet-Lysate Expanded Adipose Tissueâ€“Derived Human Mesenchymal Stromal Cells. Cartilage, 2017, 8, 283-299.	1.4	32
56	Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial. Stem Cells Translational Medicine, 2017, 6, 910-922.	1.6	31
57	Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE, 2017, 12, e0182002.	1.1	65
58	Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. PLoS ONE, 2017, 12, e0190125.	1.1	14
59	Adipose-derived mesenchymal stem cells from patients with atherosclerotic renovascular disease have increased DNA damage and reduced angiogenesis that can be modified by hypoxia. Stem Cell Research and Therapy, 2016, 7, 128.	2.4	27
60	Tracking and Therapeutic Value of Human Adipose Tissueâ€“derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology, 2016, 279, 513-522.	3.6	32
61	Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology, 2016, 87, 2230-2234.	1.5	93
62	Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Research and Therapy, 2016, 7, 107.	2.4	130
63	Su1163 Early Results Using an Adipose Derived Mesenchymal Stem Cells Coated Fistula Plug for the Treatment of Refractory Perianal Fistulizing Crohns Disease. Gastroenterology, 2016, 150, S483-S484.	0.6	6
64	Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells. Stem Cells Translational Medicine, 2016, 5, 1375-1379.	1.6	28
65	Osteogenic potential of human adipose-tissue-derived mesenchymal stromal cells cultured on 3D-printed porous structured titanium. Gene, 2016, 581, 95-106.	1.0	25
66	A novel intranuclear RNA vector system for long-term stem cell modification. Gene Therapy, 2016, 23, 256-262.	2.3	16
67	Human Adiposeâ€Derived Mesenchymal Stromal/Stem Cells Remain Viable and Metabolically Active Following Needle Passage. PM and R, 2016, 8, 844-854.	0.9	12
68	PD-1 Blunts the Function of Ovarian Tumorâ€“Infiltrating Dendritic Cells by Inactivating NF-ÎºB. Cancer Research, 2016, 76, 239-250.	0.4	84
69	Abstract A123: CD14+ monocyte recruitment, transformation and support of tumor survival in a lung cancer model. , 2016, , .		0
70	Novel cell surface markers reveal biological variability in adipose-derived mesenchymal stromal cell (AMSC) expansion: applications for regenerative cell therapy. Cytotherapy, 2015, 17, S33.	0.3	0
71	A manufacturing platform for adipose derived mesenchymal stromal cells (AdMSC) supporting clinical trials for diverse indications. Cytotherapy, 2015, 17, S39.	0.3	0
72	Innovation of mesenchymal stem cell therapies by molecular landscaping and cell surface selection. Cytotherapy, 2015, 17, S33.	0.3	0

#	Article	IF	Citations
73	Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+â€‰HLA-DRlo/neg) found in aggressive pediatric sarcoma patients. , 2015, 3, 35.		45
74	A safety study on intrathecal delivery of autologous mesenchymal stromal cells in rabbits directly supporting <scp>P</scp>hase <scp>I</scp> human trials. Transfusion, 2015, 55, 1013-1020.	0.8	25
75	Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2696-2707.	0.9	81
76	Using whole immune system characterization (immune profiling) to identify immune biomarkers to determine patient selection, dosing, and efficacy of new immune therapies. , 2015, 3, .		0
77	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans. PLoS ONE, 2015, 10, e0121546.	1.1	100
78	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 4224-4233.	3.2	33
79	Cell-based therapy in ovarian cancer: Improved adenoviral transduction strategy of human mesenchymal stem cells as tumor-homing drug factories. Gynecologic Oncology, 2015, 137, 64.	0.6	0
80	Immune independent crosstalk between lymphoma and myeloid suppressor CD14⁺HLA-DR^{low/neg}monocytes mediates chemotherapy resistance. OncoImmunology, 2015, 4, e996470.	2.1	10
81	Manufacture of monocyte-derived dendritic cells to stimulate anti-tumor immunity in Phase I trials: the mayo clinic experience. Cytotherapy, 2015, 17, S18-S19.	0.3	0
82	Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: clinical trial in progress. Cytotherapy, 2015, 17, S17.	0.3	1
83	Using comprehensive immune profiles to identify glioblastoma patients responsive to autologous dendritic cell vaccines. Cytotherapy, 2015, 17, S17.	0.3	0
84	Ligament Tissue Engineering Using a Novel Porous Polycaprolactone Fumarate Scaffold and Adipose Tissue-Derived Mesenchymal Stem Cells Grown in Platelet Lysate. Tissue Engineering - Part A, 2015, 21, 2703-2713.	1.6	20
85	Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2. Journal of Biological Chemistry, 2015, 290, 27604-27617.	1.6	144
86	Translating stem cell research to the clinic: a primer on translational considerations for your first stem cell protocol. Stem Cell Research and Therapy, 2015, 6, 146.	2.4	14
87	IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/â^' monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer Journal, 2015, 5, e328-e328.	2.8	79
88	Histone Deacetylase Inhibition Destabilizes the Multiâ€Potent State of Uncommitted Adiposeâ€Derived Mesenchymal Stromal Cells. Journal of Cellular Physiology, 2015, 230, 52-62.	2.0	46
89	Renal Vein Levels of MicroRNA-26a Are Lower in the Poststenotic Kidney. Journal of the American Society of Nephrology: JASN, 2015, 26, 1378-1388.	3.0	25
90	Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrology Dialysis Transplantation, 2014, 29, 274-282.	0.4	50

#	Article	IF	Citations
91	Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity. Cancer Immunology Research, 2014, 2, 241-248.	1.6	29
92	Immune Profiling to Predict Treatment Response from Extracorporeal Photopheresis in Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, S263.	2.0	0
93	Strategies for improving the reporting of human immunophenotypes by flow cytometry. , 2014, 2, 18.		11
94	Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response. , 2014, 2, 4.		38
95	Highâ€Resolution Molecular Validation of Selfâ€Renewal and Spontaneous Differentiation in Clinicalâ€Grade Adiposeâ€Tissue Derived Human Mesenchymal Stem Cells. Journal of Cellular Biochemistry, 2014, 115, 1816-1828.	1.2	142
96	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses. Frontiers in Immunology, 2014, 5, 147.	2.2	55
97	Lymphoma monocyte crosstalk via HSP27 to promote immune suppression and chemotherapy resistance. , 2014, 2, P222.		0
98	Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress. Blood, 2014, 124, 4474-4474.	0.6	3
99	Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Î²-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, e19539-e19539.	0.8	0
100	IL-10 Contributes to the Development of Immunosuppressive CD14+HLA-DRlow/- monocytes in B-Cell Non-Hodgkinâ€™s Lymphoma. Blood, 2014, 124, 2979-2979.	0.6	0
101	Abstract 564: Adventitial Human Mesenchymal Stem Cells Transplantation Reduces Venous Neointimal Hyperplasia in an Experimental Murine AVF Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	1.1	0
102	Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer. Journal of Translational Medicine, 2013, 11, 20.	1.8	106
103	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50
104	Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma. Cancer Research, 2013, 73, 897-907.	0.4	161
105	Data in support of the clinical use of adipose derived MSC: growth, storage, function and safety. Cytotherapy, 2013, 15, S5.	0.3	0
106	Serum-Free Medium and Mesenchymal Stromal Cells Enhance Functionality and Stabilize Integrity of Rat Hepatocyte Spheroids. Cell Transplantation, 2013, 22, 299-308.	1.2	30
107	Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study. , 2013, , .		0
108	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0

#	Article	IF	Citations
109	Soluble B7-H1: Differences in production between dendritic cells and T cells. Immunology Letters, 2012, 142, 78-82.	1.1	110
110	Association of an increased frequency of CD14⁺HLAâ€ÐR^{lo/neg} monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). British Journal of Haematology, 2012, 156, 674-676.	1.2	58
111	Abstract 4905: The BH3 mimetic navitoclax (ABT-263) selectively induces apoptosis in cholangiocarcinoma-associated fibroblasts thereby reducing tumor growth. , 2012, , .		0
112	Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells. Stem Cell Research and Therapy, 2011, 2, 46.	2.4	31
113	Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability. Cell Transplantation, 2011, 20, 797-812.	1.2	194
114	Immunosuppressive CD14+HLA-DRlow/â^' monocytes in B-cell non-Hodgkin lymphoma. Blood, 2011, 117, 872-881.	0.6	218
115	Immuno-Fluorescence Scanning Electron Microscopy of Biological Cells. Microscopy Today, 2010, 18, 8-13.	0.2	5
116	Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Research and Treatment, 2010, 122, 745-754.	1.1	71
117	Immunosuppressive CD14⁺HLAâ€ÐR^{low/â^'} monocytes in prostate cancer. Prostate, 2010, 70, 443-455.	1.2	233
118	Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology, 2010, 12, 631-644.	0.6	194
119	Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks. Clinical Cancer Research, 2010, 16, 5573-5580.	3.2	68
120	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology, 2010, 12, 351-365.	0.6	197
121	Immune Phenotyping and Naive T Cells as a Predictor of Response to Therapy In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 1362-1362.	0.6	0
122	Converting Tumor-specific Markers Into Reporters of Oncolytic Virus Infection. Molecular Therapy, 2009, 17, 1395-1403.	3.7	17
123	Carotid Repair Using Autologous Adipose-Derived Endothelial Cells. Stroke, 2009, 40, 1886-1891.	1.0	18
124	Tumorâ€associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. American Journal of Hematology, 2009, 84, 401-407.	2.0	54
125	Biâ€directional activation between mesenchymal stem cells and CLL Bâ€cells: implication for CLL disease progression. British Journal of Haematology, 2009, 147, 471-483.	1.2	74
126	Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. Clinical Cancer Research, 2009, 15, 7246-7255.	3.2	176

#	Article	IF	Citations
127	Vasoprotective effects of human CD34+ cells: towards clinical applications. Journal of Translational Medicine, 2009, 7, 66.	1.8	9
128	Clinical Grade OK432-activated Dendritic Cells. Journal of Immunotherapy, 2009, 32, 66-78.	1.2	16
129	Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood, 2009, 114, 2936-2944.	0.6	144
130	Increased Immune Suppressive CD14+ hla-DRneg Circulating Monocytes Are Found in Aggressive Non-Hodgkin's Lymphoma and Correlated with Increased Arginase I Level.. Blood, 2009, 114, 970-970.	0.6	0
131	Enhanced biological cathodoluminescence. Optics Communications, 2008, 281, 1901-1908.	1.0	28
132	A combined flow cytometryâ€“based method for fetomaternal hemorrhage and maternal D. Transfusion, 2008, 48, 1886-1891.	0.8	15
133	Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T-cell clustering. Blood, 2008, 112, 5037-5045.	0.6	52
134	Therapeutic vaccines for malignant brain tumors. Biologics: Targets and Therapy, 2008, 2, 753.	3.0	8
135	A Population of Suppressive Monocytes Inhibiting T Cell Proliferation and Dendritic Cell Differentiation in Relapsed Non-Hodgkinâ€™s Lymphoma. Blood, 2008, 112, 808-808.	0.6	0
136	Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis and Rheumatism, 2007, 56, 1658-1668.	6.7	113
137	Infrastructure Development for Human Cell Therapy Translation. Clinical Pharmacology and Therapeutics, 2007, 82, 320-324.	2.3	53
138	Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Therapy, 2007, 14, 324-333.	2.3	121
139	Sterility testing of hematopoietic progenitor cell products: a single-institution series of culture-positive rates and successful infusion of culture-positive products. Transfusion, 2007, 47, 636-643.	0.8	29
140	Tumor Associated Macrophages (TAM) in Skeletal Plasmacytomas of Patients with Multiple Myeloma.. Blood, 2007, 110, 114-114.	0.6	2
141	Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. Journal of Translational Medicine, 2006, 4, 35.	1.8	27
142	A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion, 2006, 46, 2083-2089.	0.8	113
143	Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy, 2006, 8, 290-298.	0.3	23
144	482. T Cells as Carriers for Systemic Measles Virotherapy of Multiple Myeloma. Molecular Therapy, 2006, 13, S187.	3.7	0

#	Article	IF	Citations
145	Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy, 2004, 6, 563-570.	0.3	17
146	DC in multiple myeloma immunotherapy. Cytotherapy, 2004, 6, 128-137.	0.3	15
147	Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood, 2004, 104, 1094-1099.	0.6	159
148	Imatinib Mesylate Disrupts Cell Cycle Progression, Modifies the Nucleoskeleton and Suppresses Activation-Induced Transcription in Human T Cells.. Blood, 2004, 104, 2914-2914.	0.6	0
149	A Phase I Trial of Autologous Dendritic Cell Therapy for Chronic Myelogenous Leukemia.. Blood, 2004, 104, 2931-2931.	0.6	2
150	Changes in serum VEGF and SCF during liver regeneration in humans. Gastroenterology, 2003, 124, A662.	0.6	0
151	Immunomagnetic separation reagents as markers in electron microscopy. Journal of Immunological Methods, 2002, 262, 95-101.	0.6	10
152	Cloning the cDNA for murine U2 snRNP-Aâ€² gene and its differential expression in lymphocyte development. Immunology Letters, 2002, 82, 217-223.	1.1	7
153	Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Research, 2002, 62, 6566-78.	0.4	80
154	Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous TH1 T cells. Cytotherapy, 2001, 3, 97-105.	0.3	5
155	Mature Myeloid Dendritic Cells for Clinical Use Prepared from CD14+ Cells Isolated by Immunomagnetic Adsorption. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 427-429.	1.8	20
156	Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression. Gene Therapy, 2001, 8, 419-423.	2.3	17
157	In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy, 2001, 8, 1524-1531.	2.3	166
158	Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia. Croatian Medical Journal, 2001, 42, 428-35.	0.2	6
159	Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology, 2000, 101, 53-60.	2.0	71
160	Maturation of Human Monocyte-Derived Dendritic Cells Studied by Microarray Hybridization. Biochemical and Biophysical Research Communications, 2000, 275, 731-738.	1.0	127
161	Optimizing Preparation of Normal Dendritic Cells andbcr-abl+Mature Dendritic Cells Derived from Immunomagnetically Purified CD14+Cells. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 95-101.	1.8	29
162	Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. Journal of Leukocyte Biology, 1999, 66, 909-914.	1.5	97

#	Article	IF	Citations
163	High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells. Blood, 1998, 91, 392-398.	0.6	185
164	High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells. Blood, 1998, 91, 392-398.	0.6	42
165	Genetic Association of Bovine Lymphocyte Antigen DRB3 Alleles with Immunological Traits of Holstein Cattle. Journal of Dairy Science, 1997, 80, 400-405.	1.4	84
166	Bovine Lymphocyte Antigen Class II Alleles as Risk Factors for High Somatic Cell Counts in Milk of Lactating Dairy Cows. Journal of Dairy Science, 1997, 80, 406-412.	1.4	87
167	Genetic Association Between Parameters of Innate Immunity and Measures of Mastitis in Periparturient Holstein Cattle. Journal of Dairy Science, 1997, 80, 1767-1775.	1.4	93
168	Improved Resolution of Asymmetric-PCR SSCP Products. BioTechniques, 1997, 22, 606-608.	0.8	7
169	Rapid communication: single strand conformational polymorphism (SSCP) of bovine tumor necrosis factor alpha.. Journal of Animal Science, 1997, 75, 2567.	0.2	1
170	Crohn's Disease and Ulcerative Colitis Are Associated With the DNA Repair Gene MLH1. Annals of Surgery, 1997, 225, 718-725.	2.1	43
171	Cloning and sequencing of a cDNA encoding bovine intercellular adhesion molecule 3 (ICAM-3). Gene, 1996, 174, 311-313.	1.0	5
172	Recognition of Leukochimerism during Genotyping for Bovine Leukocyte Adhesion Deficiency (BLAD) by Polymerase-Chain-Reaction-Amplified DNA Extracted from Blood. Journal of Veterinary Diagnostic Investigation, 1995, 7, 569-572.	0.5	6
173	Physical mapping of inhibin ?-A in domestic cattle. Mammalian Genome, 1993, 4, 328-332.	1.0	23
174	Microsatellite mapping of the gene causing weaver disease in cattle will allow the study of an associated quantitative trait locus.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 1058-1062.	3.3	125
175	Rapid communication: bovine dinucleotide repeat polymorphism RM004. Journal of Animal Science, 1993, 71, 3175-3175.	0.2	8
176	Rapid communication: bovine dinucleotide repeat polymorphism RM067. Journal of Animal Science, 1993, 71, 3178-3178.	0.2	8
177	Singleâ€strand conformation polymorphisms (SSCPs) detected in five bovine genes. Animal Genetics, 1993, 24, 81-84.	0.6	23
178	Isolation and mapping of polymorphic microsatellites in cattle. Animal Genetics, 1993, 24, 121-124.	0.6	144
179	Assignment of five polymorphic ovine microsatellites to bovine syntenic groups. Animal Genetics, 1993, 24, 433-436.	0.6	11
180	Somatic cell mapping, polymorphism, and linkage analysis of bovine prolactin-related proteins and placental lactogen. Genomics, 1992, 14, 137-143.	1.3	40

#	Article	IF	Citations
181	Assignment of eight loci to bovine syntenic groups by use of PCR: extension of a comparative gene map. Mammalian Genome, 1992, 3, 106-111.	1.0	33
182	RASA contains a polymorphic microsatellite and maps to bovine syntenic group U22 on Chromosome 7q2.4-qter. Mammalian Genome, 1992, 3, 559-563.	1.0	15
183	Somatic cell mapping of T-cell receptor CD3 complex and CD8 genes in cattle. Immunogenetics, 1992, 36, 224-229.	1.2	10
184	Ovine and bovine dinucleotide repeat polymorphism at the MAF46 locus. Animal Genetics, 1992, 23, 182-182.	0.6	22
185	Somatic Cell Mapping of the Bovine Somatostatin Gene. Journal of Heredity, 1989, 80, 410-412.	1.0	7